fig3

Characterization of acquired nutlin-3 resistant non-small cell lung cancer cells

Figure 3. Acquired TP53 mutations. Genes downregulated in NCI-60 cell line panel with mutated p53 (gene set: M2697) (A); mutations in the TP53 gene detected in the A549.R2 cell line (B); Western Blot analysis of p53 protein expression (C) and fluorescent intensity normalized to b-actin (D); percentage survival (E) and percentage cell death (F) of A549 and A549.R2 cells treated with APR-246 (0-50 µmol/L) for 96 h determined by the IncuCyte ZOOM cytotoxicity assay. Data presented as mean +/- SD of at least 3 biological replicates

Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/